Researchers at the University of East Anglia have developed a new nanoparticle-based cancer therapy to deliver a combination therapy directly to cancer cells.
The new therapy, which has been demonstrated to make prostate cancer and breast cancer tumors more sensitive to chemotherapy, is currently close to entering clinical trials.

Researchers at UEA’s Norwich Medical School have established that it can be mass-produced, making it a practical treatment if ascertained as effective in human trials.

Using nanoparticles to send the drugs straight into a tumor is a growing area of cancer study. The technology created at UEA is the first of its kind to use nanoparticles to transport two drugs in combination to target cancer cells.

The drugs, already permitted for clinical use, are an anti-cancer drug known as docetaxel, and fingolimod, a multiple sclerosis drug that renders tumors more sensitive to chemotherapy.

Fingolimod cannot presently be used in cancer treatment as it also overpowers the immune system, leaving patients with seriously low levels of white blood cells.
While docetaxel is used to treat a number of cancers, mainly breast, stomach, prostate, head, and neck, and a few types of lung cancers, its poisonousness can also result in severe side effects for patients whose tumors are chemo-resistant.

Since the nanoparticles created by the UEA team can deliver the drugs straight to the tumor site, these risks are greatly lowered. Furthermore, the targeted approach means less of the drug is required to destroy the cancer cells.

Image Credit:   University of East Anglia

News This Week

Nano-Enhanced Hydrogel Strategies for Cartilage Repair

A recent article in Engineering describes the development of a protein-based nanocomposite hydrogel designed to deliver two therapeutic agents—dexamethasone (Dex) and kartogenin (KGN)—to support cartilage repair. The hydrogel is engineered to modulate immune responses and promote [...]

Aging Spreads Through the Bloodstream

Summary: New research reveals that aging isn’t just a local cellular process—it can spread throughout the body via the bloodstream. A redox-sensitive protein called ReHMGB1, secreted by senescent cells, was found to trigger aging features [...]